IPO - IceCure Medical Ltd.

Form Type: F-1/A

Filing Date: 2025-07-07

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025061770

Filing Summary: IceCure Medical Ltd. is conducting a Rights Offering, allowing shareholders to purchase up to 10,000,000 Units at a subscription price of $1.00 per unit. Each Unit consists of one Ordinary Share and a warrant to purchase an additional Ordinary Share. Shareholders receive one non-transferable Subscription Right for every Ordinary Share owned as of the record date, July 9, 2025. The Subscription Rights can be exercised from July 10 to July 28, 2025. A minimum of six Subscription Rights is required to purchase one whole Unit. The company has entered into a bridge loan agreement of $2,000,000 with Epoch Partner Investments Limited, which holds a significant ownership stake in IceCure. The registration statement is filed under the Securities Act of 1933, indicating an initial public offering (IPO) or similar equity offering for funding purposes. The company is categorized as an emerging growth company and aims to use proceeds for repaying the bridge loan and general operational needs.

Form Type: F-1/A

Filing Date: 2025-07-03

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025061361

Filing Summary: IceCure Medical Ltd. is conducting a Rights Offering for shareholders, distributing non-transferable subscription rights to purchase up to 10,000,000 units at a price of $1.00 per unit. Each unit consists of one ordinary share and one warrant to purchase an additional ordinary share. Shareholders will receive one subscription right for each ordinary share owned as of the record date, July 9, 2025. Shareholders must exercise at least six subscription rights to purchase one unit. The subscription period runs from July 10 to July 28, 2025. If fully subscribed, the offering will result in maximum proceeds of $10,000,000. Epoch Partner Investments has committed to a standby purchase of up to $5,000,000. The proceeds will be used to repay a bridge loan and for general corporate purposes. The company is classified as an emerging growth company and has not yet listed the warrants or pre-funded warrants on any exchange. This offering is intended to strengthen the company's capital position as it moves forward with its cryoablation technology for treating tumors.

Form Type: F-1/A

Filing Date: 2025-06-25

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025057495

Filing Summary: IceCure Medical Ltd. filed Amendment No. 1 to Form F-1 on June 25, 2025, to register securities under the Securities Act of 1933. The company is conducting a Rights Offering, distributing non-transferable subscription rights to purchase up to 10,000,000 Units at a subscription price of $1.00 per Unit, which includes Ordinary Shares and Warrants. The Rights Offering will commence on July 10, 2025, and end on July 28, 2025. Each shareholder will receive one subscription right for every one Ordinary Share owned as of the record date of July 9, 2025. The company aims to use proceeds from this offering to repay a bridge loan and for general corporate purposes. The offering will be managed by Maxim Group LLC. Epoch Partner Investments Limited has committed to participate in the offering, intending to purchase up to $5,000,000 worth of Units. The process is subject to various conditions, including the non-transferable nature of the subscription rights and the cancellation, modification, or amendment of the Rights Offering prior to expiration.

Form Type: F-1

Filing Date: 2025-06-16

Corporate Action: Ipo

Type: New

Accession Number: 000121390025054497

Filing Summary: IceCure Medical Ltd. has filed a registration statement for an initial public offering (IPO) of non-transferable subscription rights offering to purchase units consisting of ordinary shares and warrants. The filing includes an aggregate amount of $10,000,000 for the subscription rights. Each shareholder will receive one subscription right for each ordinary share owned on the record date. The subscription rights can be exercised at a specified price per unit, with opportunities provided for over-subscription privileges if the rights are not fully exercised by others. The offering aims to raise funds to repay a bridge loan and for general corporate purposes. Information on the associated warrants and the subscription process is extensively detailed, outlining a unique call feature dependent on certain conditions related to FDA marketing authorization and share price performance. The rights offering will commence and the exact dates for subscription exercises and unit deliveries will be announced subsequent to this filing.

Form Type: 424B5

Filing Date: 2025-01-13

Corporate Action: Ipo

Type: New

Accession Number: 000121390025002851

Filing Summary: IceCure Medical Ltd. has entered into an equity distribution agreement with Maxim Group LLC on January 13, 2025, for the sale of ordinary shares valued at up to $13,960,500. The agreement allows IceCure to conduct sales through an 'at the market offering' as described in Rule 415 of the Securities Act of 1933. The Sales Agent will earn a commission of 2.5% of the gross sales price per share sold. As of January 10, 2025, IceCure had 56,568,999 ordinary shares outstanding and intends to use the proceeds for research, development, marketing, and general corporate purposes. The company also notes significant risks related to investing due to the regional instability in Israel, including the ongoing conflict with Hamas, which may impact its operations and business continuity.